myTomorrows has introduced a next-generation AI platform designed to revolutionize clinical trial recruitment by addressing the growing complexity of patient-trial matching and accessibility challenges in the healthcare ecosystem.
The platform's AI pre-screening tool demonstrates 98% accuracy in trial eligibility checks, surpassing both industry benchmarks and medically trained professionals. This advancement comes at a crucial time when the proliferation of disease subtypes and increasingly intricate eligibility criteria have made clinical trial navigation particularly challenging for healthcare providers.
Michel van Harten, MD, CEO of myTomorrows, explained the platform's significance: "Physicians are committed to providing the best care for their patients, yet many lack the time to navigate the complex clinical trial landscape. This gap results in increased workloads, lower enrollment success rates, and missed opportunities for patients. Our AI-powered platform removes barriers by streamlining trial searches, pre-screening, and referrals—all within a secure, end-to-end solution. Built as a foundation for future agentic AI applications, it represents a bold step toward the future of clinical trial access."
The technology integrates comprehensive features that source trials from global registries including ClinicalTrials.gov, EudraCT, and ISRCTN. It matches patient medical data against trial criteria while maintaining robust security measures, including ISO 27001 certification and compliance with GDPR and HIPAA regulations. The platform's capabilities extend to real-time clinical trial data analysis, providing insights into investigational drugs' mechanisms of action, efficacy, and safety profiles.
Internal testing has validated the AI's performance across nine disease areas and 490 trials, demonstrating its superiority over the Harvard n2c2 benchmark. The platform will be showcased at the SCOPE Summit in Orlando, Florida, on February 6, 2025, where it will demonstrate its ability to facilitate immediate trial identification and candidate referrals.
Looking ahead, myTomorrows plans to extend platform access to enterprises, including hospitals, Clinical Research Organizations (CROs), patient advocacy groups, and healthtech companies. Dr. van Harten emphasized their mission: "At myTomorrows, we are purpose-driven, committed to serving and connecting all stakeholders across the care continuum. Our technology unlocks immense efficiency gains while ensuring more qualified patients gain timely access to clinical trials."
Click here for the original news story.